Chugai's profit ahead of target in difficult first half
This article was originally published in Scrip
Chugai's net profit in the first half to June 30th came in ¥3.4 billion ahead of the company's own forecast at ¥18.9 billion ($177.6 million), but still fell 10% short of last year's figure, hit by sharply lower sales of Tamiflu (oseltamivir).
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.